CVS enhances Hep C CareTeam
WOONSOCKET, R.I. — CVS Caremark is enhancing its hepatitis C patient support program following the recent Food and Drug Administration approval of two new add-on therapies for hepatitis C, the company announced on Friday.
While the new therapies offer improved response rates and a shorter treatment regimen for patients, they still result in uncomfortable and challenging side effects. The Hep C CareTeam educates patients about their disease and treatment regimen and supports them throughout therapy. The team also researches and manages the benefits verification process, ensures on-time delivery of the medication, coordinates injection training for new patients and communicates proactively with the patient’s physician.
"As the treatment landscape for hepatitis C changes with the addition of two new therapies, we see an even greater need to provide patients with support to help them manage their medications and stay adherent," CVS Caremark specialty pharmacy operations SVP Scott Reid said. "Our CareTeam approach connects patients with a dedicated team, including a nurse and specially trained pharmacists that are available to provide support 24 hours a day, 365 days a year."
The CVS Caremark Specialty Pharmacy Hep C CareTeam is comprised of nurses, pharmacists and pharmacy service representatives. These professionals are focused on the treatment of hepatitis C and undergo training and education related to the disease and available therapies. The Hep C CareTeam reinforces the physician’s instructions to make sure the patient safely and effectively administers their prescribed medication and proactively communicates with the physician as needed to address any treatment related issues or complications that may arise.
Hepatitis C is the most common blood-borne viral infection in the United States. Current estimates suggest that approximately 3.2 million Americans may be infected with the virus, many of whom are unaware they have the disease because they do not experience any symptoms. Traditional therapies for the disease have low response rates and often have significant side effects (primarily flu-like symptoms) that cause the patient to feel worse during therapy and may contribute to nonadherence. In fact, only about 25% of patients who initiate therapy complete the full treatment regimen.
Pfizer looks to block Watson from launching generic Viagra
PARSIPPANY, N.J. — Generic drug maker Watson Labs is hoping to market a generic version of a Pfizer drug for erectile dysfunction.
Watson announced Thursday that it had filed a regulatory approval application with the Food and Drug Administration to market a generic version of Viagra (sildenafil citrate) tablets in 25-mg, 50-mg and 100-mg strengths.
Pfizer filed suit against Watson on Wednesday in the U.S. District Court for the Southern District of New York seeking to prevent Watson from commercializing its version of the drug before the expiration of one of Pfizer’s patents, U.S. Patent No. 6,469,012, scheduled to expire in October 2019, according to FDA records. The lawsuit prevents the FDA from approving Watson’s product until November 2013 or until the companies resolve the matter before the court.
Viagra had U.S. sales of slightly more than $1 billion during the 12-month period ended in April, according to IMS Health.
HbA1C test may not be useful among dialysis patients with diabetes
WINSTON-SALEM, N.C. — The gold standard long-term glucose monitoring test for patients with diabetes proved to be of limited value in dialysis patients, according to a new study at Wake Forest Baptist Medical Center released Wednesday.
While the American Diabetes Association has deemed the hemoglobin A1C test an effective tool for diagnosing diabetes, kidney doctors recently determined that the HbA1C test is not as useful for managing patients with diabetes and advanced kidney failure. Another test, the glycated albumin, or GA, assay appears to be far more effective in this setting.
“Many organs don’t function properly in severe kidney failure," said Barry Freedman, John H. Felts III professor of internal medicine and lead investigator of the study. “For example, most dialysis patients have anemia with fewer red blood cells than they should, which has a dramatic impact on the accuracy of the HbA1C reading.
“This is the first study showing that a blood sugar test predicts risk of death in diabetic dialysis patients, as well as risk of hospitalization,” Freedman said. “This test provides the missing link that will allow dialysis patients and physicians to accurately gauge risk. The association is clear: high GA readings predict higher risk.”
Nearly 500,000 people are on dialysis in the United States, and diabetes is the cause of kidney failure in nearly 50% of them. Diabetes is the most common cause of kidney failure worldwide and is associated with high mortality rates — more than 20% of dialysis patients die each year.
Patients and physicians rely on the HbA1C test to measure an individual’s average blood sugar level over the prior three months. It is the most commonly used long-term blood sugar test, and is widely trusted in the medical community.
Freedman suggested physicians not rely on the HbA1C in dialysis patients, instead suggesting that blood-glucose levels be monitored directly with multiple daily readings until the GA test is available in the states.